Open Label, Randomized, Parallel Group, Single Dose, 2-Way Comparison Bioequivalence Study of Certolizumab Pegol Solution Injected Either by a Pre-Filled Syringe (Reference) or by an Auto Injection Device (Test) to Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2018
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors UCB
- 07 Jun 2018 According to the UCB media release, data from this study will be presented at the Annual European Congress of Rheumatology (EULAR 2018).
- 20 Feb 2009 New trial record